What should the nurse do if a client experiences dizziness during aminoglycoside treatment?

During aminoglycoside treatment, if a client experiences dizziness, the appropriate action is to notify the healthcare provider and hold treatment. Aminoglycosides, such as gentamicin and tobramycin, are known to potentially cause ototoxicity, which can lead to issues like dizziness, tinnitus, and even hearing loss. The occurrence of dizziness signals the possibility of adverse effects related to the medication.

Holding treatment is crucial because continuing the medication without consulting the healthcare provider might worsen the situation or lead to more severe side effects. By notifying the healthcare provider, the nurse ensures that further evaluation can be conducted to determine the cause of the dizziness and whether it is safe to continue the medication or if an alternative treatment plan is needed. This approach prioritizes patient safety and addresses the risk of potential complications from aminoglycoside therapy.